Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine

[JIDD]

Research from National and Kapodistrian University of Athens on first dose effects of both AZ and Pfizer vaccines looks guardedly positive.

link.springer.com/article/1...

Here's the final para -

In summary, the antibody-mediated response to SARS-CoV-2 vaccines in patients with WM/CLL/NHL is considerably affected by both the underlying disease and the treatment. Even though the response rates were not optimal, vaccination is still considered essential and if possible should be performed before treatment initiation. These patients with suboptimal responses should be considered to be prioritized for booster doses, potentially with a different vaccine type [26]. For these patients prolonged self-protection measures, such as mask wearing and social distancing, are necessary.

I could not see any indication that research would re-survey after second jabs but I guess that is likely.

The refereence is -

26. Borobia AM, Carcas AJ, Perez-Olmeda M et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 2021;398(10295):121–30. [see covid19.ccg.unam.mx/repocli...]

- which research in Spain on a two jab strategy, Pfizer followed by AZ.

[Fran57]

Thank you for taking the trouble to post this…some interesting information.Stay safe,

Fran 😉